Amgen submits applications in the US and Europe to expand current indication for Xgeva
Applications include data from the largest international trial conducted in multiple myeloma.
Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA and an application for a variation to the marketing authorization to the EMA for Xgeva (denosumab). The submissions to regulatory authorities seek to expand the currently approved Xgeva indication for the prevention of skeletal-related events (SREs) in solid tumours to include patients with multiple myeloma. The applications include new data from the pivotal Phase III head-to-head '482 study, the largest international multiple myeloma trial ever conducted.
Xgeva is a fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL) - a protein essential for the formation, function and survival of osteoclasts, which break down bone - thereby inhibiting osteoclast-mediated bone destruction. Xgeva is currently indicated for the prevention of SREs in patients with bone metastases from solid tumors based on results from three previous pivotal Phase III head-to-head studies. In these Phase III studies, Xgeva demonstrated superiority in the solid tumours studied compared to zoledronic acid. In the US, Xgeva has a limitation of use noting that it is not indicated for the prevention of SREs in patients with multiple myeloma.
"Bone lesions are a hallmark of multiple myeloma and often result in bone complications, which can be devastating for patients. Current treatment options for bone complications are limited to bisphosphonates, which are associated with renal toxicity. Approximately 60% of all multiple myeloma patients have or will develop renal impairment over the course of the disease," said Sean E. Harper, executive vice president of R&D at Amgen. "Xgeva's unique mechanism of action may offer multiple myeloma patients a novel treatment option that is not renally cleared. We look forward to collaborating with regulatory authorities to make Xgeva available to this patient population with an important unmet medical need."
The sBLA is based on efficacy and safety data from the pivotal Phase III '482 study, which demonstrated that Xgeva is non-inferior to zoledronic acid in delaying the time to first on-study SRE in patients with multiple myeloma. The secondary endpoints of superiority in delaying time to first SRE and delaying time to first-and-subsequent SRE were not met in this study. Overall survival (OS), another secondary endpoint, was also in favour of Xgeva over zoledronic acid; however, it was not statistically significant. The hazard ratio of Xgeva versus zoledronic acid for progression-free survival (PFS) was 0.82. The median PFS difference between arms was 10.7 months in favour of Xgeva. These results were presented during the late-breaking abstract session at the 16th International Myeloma Workshop.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance